BioTuesdays

Category - Markets

Albireo Pharma Logo
Markets

HCW starts Albireo Pharma at buy; PT $62

H.C. Wainwright launched coverage of Albireo Pharma (NASDAQ:ALBO) with a “buy” rating and $27 price target. The stock closed at $26.80 on Feb. 27. Albireo is focused on rare pediatric and adult cholestatic diseases...

February 28, 2019
Corindus Logo
Markets

Corindus Vascular Robotics closes private placement

Corindus Vascular Robotics (NYSE American:CVRS) privately sold 10,872,716 of its common shares at a price of $1.3796 each to a large institutional investor for gross proceeds of about $15-million. Net proceeds of about...

February 26, 2019
Pulse Biosciences Logo
Markets

HCW starts Pulse Biosciences at buy; PT $27

H.C. Wainwright launched coverage of Pulse Biosciences (NASDAQ:PLSE) with a “buy” rating and price target of $27. The stock closed at $18.23 on Feb. 22. Analyst Swayampakula Ramakanth writes that his recommendation is...

February 25, 2019
BioTime
Markets

HCW starts BioTime at buy; PT $4

H.C. Wainwright launched coverage of BioTime (NYSE American:BTX) with a “buy” rating and $4 price target. The stock closed at $1.15 on Feb. 20. Analyst Joseph Pantginis writes that BioTime was originally focused on...

February 21, 2019
Arcturus Logo
Markets

Roth starts Arcturus Therapeutics at buy; PT $14

Roth Capital Partners launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $14 price target. The stock closed at $4.84 on Feb. 19. “Arcturus is a hidden gem in a sea of RNA medicines...

February 20, 2019
Homology Logo
Markets

HCW starts Homology Medicines at buy; PT $36

H.C. Wainwright initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $36 price target. The stock closed at $24.03 on Feb. 19. Analyst Debjit Chattopadhyay writes that Homology’s platform...

February 20, 2019
Markets

Roth starts Chiasma at buy; PT $16

Roth Capital Partners initiated coverage of Chiasma (NASDAQ:CHMA) with a “buy” rating and $16 price target. The stock closed at $3.87 on Feb. 15. “With two Phase 3 readouts on the horizon, Chiasma is a fallen angel...

February 19, 2019